共 63 条
[1]
Orange JS(2012)Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy Clin Exp Immunol 169 172-181
[2]
Belohradsky BH(2010)Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies Clin Immunol 137 21-30
[3]
Berger M(2015)Therapeutic immunoglobulin should be dosed by clinical outcome rather than by body weight in obese patients Clin Exp Immunol 181 179-187
[4]
Borte M(2011)Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose Curr Opin Allergy Clin Immunol 11 532-538
[5]
Hagan J(2014)Dose and outcomes in primary immunodeficiency disorders Clin Exp Immunol 178 7-9
[6]
Jolles S(2013)Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease J Clin Immunol 33 S90-S94
[7]
Orange JS(2017)Considerations for dosing immunoglobulin in obese patients Clin Exp Immunol 188 353-362
[8]
Grossman WJ(2013)Impact of ideal body weight dosing for all inpatient i.v. immune globulin indications Am J Health Syst Pharm 70 751-752
[9]
Navickis RJ(2004)The assessment and management of primary antibody deficiency NZ Med J 117 U914-211
[10]
Wilkes MM(2013)New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin Clin Exp Immunol 174 203-266